These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 31678770)

  • 1. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The consensus molecular subtypes of colorectal cancer.
    Guinney J; Dienstmann R; Wang X; de Reyniès A; Schlicker A; Soneson C; Marisa L; Roepman P; Nyamundanda G; Angelino P; Bot BM; Morris JS; Simon IM; Gerster S; Fessler E; De Sousa E Melo F; Missiaglia E; Ramay H; Barras D; Homicsko K; Maru D; Manyam GC; Broom B; Boige V; Perez-Villamil B; Laderas T; Salazar R; Gray JW; Hanahan D; Tabernero J; Bernards R; Friend SH; Laurent-Puig P; Medema JP; Sadanandam A; Wessels L; Delorenzi M; Kopetz S; Vermeulen L; Tejpar S
    Nat Med; 2015 Nov; 21(11):1350-6. PubMed ID: 26457759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications.
    Wang F; Gao X; Wang P; He H; Chen P; Liu Z; Chen Y; Zhou H; Chen W; Yi X; Xia X; Liu S
    Front Immunol; 2022; 13():877896. PubMed ID: 35720373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel TGF-β-Related Signature for Predicting Prognosis, Tumor Microenvironment, and Therapeutic Response in Colorectal Cancer.
    Tao B; Yi C; Ma Y; Li Y; Zhang B; Geng Y; Chen Z; Ma X; Chen J
    Biochem Genet; 2024 Aug; 62(4):2999-3029. PubMed ID: 38062276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy.
    Becht E; de Reyniès A; Giraldo NA; Pilati C; Buttard B; Lacroix L; Selves J; Sautès-Fridman C; Laurent-Puig P; Fridman WH
    Clin Cancer Res; 2016 Aug; 22(16):4057-66. PubMed ID: 26994146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A High RORγT/CD3 Ratio is a Strong Prognostic Factor for Postoperative Survival in Advanced Colorectal Cancer: Analysis of Helper T Cell Lymphocytes (Th1, Th2, Th17 and Regulatory T Cells).
    Yoshida N; Kinugasa T; Miyoshi H; Sato K; Yuge K; Ohchi T; Fujino S; Shiraiwa S; Katagiri M; Akagi Y; Ohshima K
    Ann Surg Oncol; 2016 Mar; 23(3):919-27. PubMed ID: 26564244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic β-catenin signaling suppresses CD8
    Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
    Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.
    Jackstadt R; van Hooff SR; Leach JD; Cortes-Lavaud X; Lohuis JO; Ridgway RA; Wouters VM; Roper J; Kendall TJ; Roxburgh CS; Horgan PG; Nixon C; Nourse C; Gunzer M; Clark W; Hedley A; Yilmaz OH; Rashid M; Bailey P; Biankin AV; Campbell AD; Adams DJ; Barry ST; Steele CW; Medema JP; Sansom OJ
    Cancer Cell; 2019 Sep; 36(3):319-336.e7. PubMed ID: 31526760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.
    Lal N; White BS; Goussous G; Pickles O; Mason MJ; Beggs AD; Taniere P; Willcox BE; Guinney J; Middleton GW
    Clin Cancer Res; 2018 Jan; 24(1):224-233. PubMed ID: 29061646
    [No Abstract]   [Full Text] [Related]  

  • 11. TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer.
    Yang M; Huang Q; Li C; Jiang Z; Sun J; Wang Z; Liang R; Li D; Li B; Zhao H
    Front Immunol; 2021; 12():647540. PubMed ID: 33897695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucinous adenocarcinoma of the colon and rectum: A genomic analysis.
    Reynolds IS; O'Connell E; Fichtner M; McNamara DA; Kay EW; Prehn JHM; Furney SJ; Burke JP
    J Surg Oncol; 2019 Dec; 120(8):1427-1435. PubMed ID: 31729037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune gene signature delineates a subclass of thyroid cancer with unfavorable clinical outcomes.
    Zhi J; Yi J; Tian M; Wang H; Kang N; Zheng X; Gao M
    Aging (Albany NY); 2020 Apr; 12(7):5733-5750. PubMed ID: 32240105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
    Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
    Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenoma to carcinoma: A portrait of molecular and immunological profiles of colorectal sporadic tumors.
    Elsayed I; Li L; Sheahan K; Moran B; Bakheit S; Wang X
    Int Immunopharmacol; 2021 Nov; 100():108168. PubMed ID: 34562842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathological classification of colorectal cancer.
    Müller MF; Ibrahim AE; Arends MJ
    Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases.
    Zhang Y; Song J; Zhao Z; Yang M; Chen M; Liu C; Ji J; Zhu D
    Cancer Lett; 2020 Feb; 470():84-94. PubMed ID: 31610266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host-microbiota interactions contributing to the heterogeneous tumor microenvironment in colorectal cancer.
    Li X; Wu D; Li Q; Gu J; Gao W; Zhu X; Yin W; Zhu R; Zhu L; Jiao N
    Physiol Genomics; 2024 Feb; 56(2):221-234. PubMed ID: 38073489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment.
    Akimoto M; Maruyama R; Takamaru H; Ochiya T; Takenaga K
    Nat Commun; 2016 Nov; 7():13589. PubMed ID: 27882929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.